



Best Women's Health Pharmaceutical Company - Quebec

EndoCeutics is a research and development company predominantly focused on the field of woman's health. Dr. Labrie talks us through the firm and the research it undertakes in this vital area.

EndoCeutics is a private pharmaceutical company operating in the field of women's health and hormone-sensitive cancer prevention and treatment. The firm is the world leader in the mechanism of action of sex steroids.

Following approval by the FDA of Intrarosa™ in November 2016, for the treatment of dyspareunia, a predominant symptom of vulvovaginal atrophy due to menopause, EndoCeutics focuses on developing non estrogen-based therapies for sexual dysfunction and the other symptoms of menopause, including hot flashes, osteoporosis and muscle loss. Hormonal therapies for breast, uterine and prostate cancer, male hypogonadism as well as endometriosis are also under development. Dr. Labrie, one of the most accomplished researchers in the international scientific community, discusses the implications this innovative new treatment has for women's health.

“There are 32 million women in the United States who could benefit from Intrarosa™. Intrarosa™ is a non-estrogenic treatment for vulvovaginal atrophy. This treatment uses Prasterone (DHEA), a compound without intrinsic estrogenic or androgenic activity which is transformed intracellularly into androgens and estrogens only in the cells and vaginal layers physiologically in need of these sex steroids. This innovative treatment provides a replacement for the local deficiency in sex steroids with no significant increase in circulating estrogens or androgens and consequently, no effect in the other tissues.

“In addition, positive effects are observed on the four domains of sexual dysfunction, namely desire, arousal, orgasm and pleasure, an effect secondary to local androgen formation and not found with estrogens. These observations are under evaluation by EndoCeutics.”

Moving forward, Dr. Labrie foresees exciting times ahead as his firm seeks to bring Intrarosa™ to market and potentially change the lives of millions of women around the world.

“Looking to the future, we believe that the female health market will be dominated by a focus on creating novel treatments for all aspects of menopause based upon intracrinology or the normal physiology of sex steroids. In order to keep ahead of this emerging development, we will be seeking to explore more clinical applications using the best technology. Change is

central to improving the lives of women across the globe, and as such we will embrace this strategy as we seek to be the leaders of innovations on the pharmaceutical market.

“Our overall aim is to be able to offer all women around the world the benefits of an efficacious and safe treatment of menopause. We have a strong desire to move science forward for a better life of our fellow citizens, and this will remain our ongoing goal.”

About 2017 North American Excellence Awards

Over the past few years North American businesses have been one of the leading lights of the business domain. Despite the challenges and uncertainty that the industry faces, both these companies and individuals refuse to let anything cease them from achieving true excellence in their respective sectors.

Therefore, the 2017 North American Excellence Awards honor the companies and individuals within the business industry, whose consistency to provide exceptional service has been the driving force behind their innovation and commitment to thrive within the sector. Regardless of the size of the firm, the age or even their specialization, these awards are centred around rewarding those whose stunning achievements have been the outcome of tireless efforts and passion for their work.

As such, these awards are handed out solely on merit and are awarded to commend those who are truly deserving for their remarkable service over the past 12 months. Once the voting closes our dedicated research team is set to work, leaving no stone unturned to ensure that all of our winners can be rest assured that their win was truly deserved.

About Endoceutics

Endoceutics is a private pharmaceutical company operating in the field of women’s health and hormone-sensitive cancer prevention and treatment. Following approval by the FDA of Intrarosa™ in November 2016, for the treatment of dyspareunia, a symptom of vulvovaginal atrophy due to menopause, Endoceutics focuses on developing non estrogen-based therapies for sexual dysfunction and the other symptoms of menopause, , including hot flushes, osteoporosis, muscle loss and type 2 diabetes. Hormonal therapies for breast, uterine and prostate cancer, male hypogonadism as well as endometriosis are also under development. Endoceutics has five Phase III product candidates addressing large market opportunities and two Phase I/II product candidates. Endoceutics has exclusive worldwide rights to patents, patent applications, technology and know-how related to all its products.

Contact for Endoceutics:

info@endoceutics.com

Tel (418) 653-0033